Alloimmunity & Trauma

Team Pham

09 November, 2018

Contents

Table 1: Demographics

	Anti- (3947)	Anti+ (185)	p^a
Age (years) (mean (sd))	47.33 (19.15)	50.39 (19.93)	0.034
Gender (% male)	2814 (71.3)	121 (65.4)	0.100
Ethnicity (% African American)	2773 (70.3)	130 (70.3)	1.000
Mortality (%)	447 (11.3)	39 (21.1)	<0.001
Length of admission (median [IQR])	11.58 [5.96, 22.13]	30.72 [16.45, 53.43]	<0.001
Number of RBC transfusion (median [IQR])	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	<0.001
Number of Type & Screen tests performed (median [IQR])	1.00 [0.00, 2.00]	3.00 [1.00, 7.00]	<0.001

1

Table 2: Demographics Option

	Anti- (3947)	Anti+ (185)	p^a
Age (years) (mean (sd))	47.33 (19.15)	50.39 (19.93)	0.034
Gender (% male)	2814 (71.3)	121 (65.4)	0.100
Ethnicity (% African American)	2773 (70.3)	130 (70.3)	1.000
Mortality (%)	447 (11.3)	39 (21.1)	<0.001
Length of admission (median [IQR])	11.58 [5.96, 22.13]	30.72 [16.45, 53.43]	<0.001
Number of RBC transfusion (mean (sd))	0.14 (1.02)	1.75 (7.23)	<0.001
Number of Type & Screen tests performed (median [IQR])	1.00 [0.00, 2.00]	3.00 [1.00, 7.00]	<0.001

Table 3: Antibody Specificity

Antibody	Frequency
Anti-A	1
Anti-C	13
Anti-D	13
Anti-E	42
Anti-F	4
Anti-H	1
Anti-J	10
Anti-K	13
Anti-L	12
Anti-M	9
Anti-N	57
Anti-S	1
Anti-V	1
Anti-W	16

Table 4: Transfusion and Antibody Development

Number of RBC transfusion	% Developed Antibody During Encounter
0	4.218237
1-5	3.846154
6-10	14.814815
11-20	30.000000
>20	100.000000

Tables

Table 4: Outcomes analysis

Supplemental Figure 1: Antibody Frequency by Gender

Antibody	Frequency
Anti-A	1
Anti-C	13
Anti-D	13
Anti-E	42
Anti-F	4
Anti-H	1
Anti-J	10
Anti-K	13
Anti-L	12
Anti-M	9
Anti-N	57
Anti-S	1
Anti-V	1
Anti-W	16

Supplemental Figure 2: Antibody Frequency by Race